Raltegravir
Raltegravir
Klass : A
Visa all info
Skriv ut
Kontakta oss
Produkter
ISENTRESS
ISENTRESSATC-koder
J05AJ01
J05AJ01Substanser
raltegravir, raltegravirkalium
raltegravir, raltegravirkaliumSammanfattning
Inga skillnader mellan män och kvinnor har rapporterats avseende farmakokinetiska parametrar eller effekt av raltegravir. Mindre observationella studier visar på mer gastrointestinala biverkningar hos kvinnor och mer muskelbesvär och kreatininkinasstegring hos män.
Inga skillnader mellan män och kvinnor har rapporterats avseende farmakokinetiska parametrar eller effekt av raltegravir. Mindre observationella studier visar på mer gastrointestinala biverkningar hos kvinnor och mer muskelbesvär och kreatininkinasstegring hos män.Background
Antiretrovirals for treatment of HIV are always given as a combination of at least three medicines. Cobicistat is used to boost the effect of other antiretroviral drugs. As studies on HIV patients always include patients receiving combination therapy it is difficult to know which of the studied medicines that cause changes in effect and/or adverse events. Visa hela bakgrundstexten
Pharmacokinetics and dosing
The producer reports no differences between men and women in pharmacokinetic variables and does not recommend differences in dosing according to patient’s sex [1]. In a multicenter, open-label one arm study of raltegravir in HIV patients (109 men, 97 women) pharmacokinetic variables were similar in men and women [2].
Effects
No sex differences were found in an Italian observational cohort study of determinants of virological failure in triple-class experienced patients receiving raltegravir-based regimens (69 men, 32 women) [3]. Similarly, in a multicenter, open-label one arm study of raltegravir in HIV patients (109 men, 97 women) virologic response was found to be similar in men and women [2].
# Adv......
Försäljning på recept
Visa hela försäljning på recept
Fler män än kvinnor hämtade ut läkemedel innehållande raltegravir (ATC-kod J05AX08) på recept i Sverige år 2017, totalt 303 män och 142 kvinnor [6].
Referenser
Visa referenser
Isentress (raltegravir). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.
Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F et al. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. AIDS Res Hum Retroviruses. 2013;29(6):859-70.
Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE et al. Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. Int J STD AIDS. 2012;23(7):459-63.
Madeddu G, De Socio GV, Ricci E, Quirino T, Orofino G, Carenzi L et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents. 2015;45(3):289-94.
Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.
Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]
- Isentress (raltegravir). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.
- Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F et al. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. AIDS Res Hum Retroviruses. 2013;29(6):859-70.
- Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE et al. Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. Int J STD AIDS. 2012;23(7):459-63.
- Madeddu G, De Socio GV, Ricci E, Quirino T, Orofino G, Carenzi L et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents. 2015;45(3):289-94.
- Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]
Uppdaterat
Litteratursökningsdatum: 7/18/2018
Litteratursökningsdatum: 7/18/2018Fasstexter
Visa fasstexter